Exact Sciences (EXAS) Down 1.4% Since Last Earnings Report: Can It Rebound?

Zacks2021-06-03

A month has gone by since the last earnings report for Exact Sciences (EXAS). Shares have lost about 1.4% in that time frame, underperforming the S&P 500. Will the recent negative trend continue ...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2140420519?lang=zh_CN&edition=full","thumbnail":"https://s.yimg.com/uu/api/res/1.2/f_bLTsOnmzrA8rHMNKfNRw--~B/aD01OTQ7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://s.yimg.com/uu/api/res/1.2/Fj4TPQveJWuth16WIsEVAw--~B/aD01OTQ7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/46ebfcbff417ac1bbde85ad33fa0d4be","is_english":true,"pubTime":"2021-06-03 23:31","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2140420519","market":"us","top_or_hot":-1,"title":"Exact Sciences (EXAS) Down 1.4% Since Last Earnings Report: Can It Rebound?","media":"Zacks","content":"<div>\n<p>A month has gone by since the last earnings report for Exact Sciences (EXAS). Shares have lost about 1.4% in that time frame, underperforming the S&P 500.\nWill the recent negative trend continue ...</p>\n\n<a href=\"https://finance.yahoo.com/news/exact-sciences-exas-down-1-153103552.html\">网页链接</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Exact Sciences (EXAS) Down 1.4% Since Last Earnings Report: Can It Rebound?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nExact Sciences (EXAS) Down 1.4% Since Last Earnings Report: Can It Rebound?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-03 23:31 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/exact-sciences-exas-down-1-153103552.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>A month has gone by since the last earnings report for Exact Sciences (EXAS). Shares have lost about 1.4% in that time frame, underperforming the S&P 500.\nWill the recent negative trend continue ...</p>\n\n<a href=\"https://finance.yahoo.com/news/exact-sciences-exas-down-1-153103552.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"EXAS","symbol_name":"精密科学","start_time":0,"source_url":"https://finance.yahoo.com/news/exact-sciences-exas-down-1-153103552.html","article_id":"2140420519","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/f_bLTsOnmzrA8rHMNKfNRw--~B/aD01OTQ7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://s.yimg.com/uu/api/res/1.2/Fj4TPQveJWuth16WIsEVAw--~B/aD01OTQ7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/46ebfcbff417ac1bbde85ad33fa0d4be"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2140420519","pubTimestamp":1622734263,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"A month has gone by since the last earnings report for Exact Sciences (EXAS). Shares have lost about","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"EXAS":"精密科学"},"translate_title":"Exact Sciences(EXAS)自上次财报以来下跌1.4%：它能反弹吗？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EXAS":1},"content_text":"A month has gone by since the last earnings report for Exact Sciences (EXAS). Shares have lost about 1.4% in that time frame, underperforming the S&P 500.\nWill the recent negative trend continue leading up to its next earnings release, or is Exact Sciences due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important drivers. \nExact Sciences Q1 Earnings Top Estimates, Margins Down\nExact Sciences Corporation reported first-quarter 2021 net loss of 18 cents, narrower than the net loss of 91 cents in the year-ago period. The quarter’s net loss was also narrower than the Zacks Consensus Estimate of a loss of $1.04.\nRevenues in Detail\nFirst-quarter consolidated revenues were $402.1 million, up 15.6% year over year. The metric exceeded the Zacks Consensus Estimate by 4.5%.\nSegments in Detail\nScreening revenues, which include laboratory service revenues from Cologuard and revenues from Biomatrica products, were $240.3 million, reflecting a year-over-year increase of 10%.\nPrecision Oncology revenues, which include laboratory service revenues from global Oncotype products, were $129.4 million. Revenues from COVID-19 testing totaled $32.3 million.\nMargin\nIn the quarter under review, Exact Sciences’ gross profit (excluding the amortization of acquired intangibles) rose 9.7% to $292.1 million. However, gross margin contracted 389 basis points (bps) to 72.6% on a 34.7% surge in total cost.\nResearch and development expenses surged a stupendous 165.6% year over year to $115.7 million. Sales and marketing expenses rose 10.9% to $186.1 million. General and administrative expenses surged 135% to $267.7 million year over year.\nAdjusted operating expenses were $569.4 million in the first quarter, up 75.1% year over year. Adjusted operating loss totaled $277.4 million, wider than the year-ago operating loss of $59 million.\nFinancial Update\nExact Sciences exited first-quarter 2021 with cash and cash equivalents, and marketable securities of $1.38 billion compared with $1.84 billion at the end of fourth-quarter 2020.\nLong-term debt (excluding the current portion) at the end of first-quarter 2021 was $22 million compared with $22.3 million at the end of fourth-quarter 2020.\n2021 Outlook\nFor 2021, the company has provided its financial outlook. The company expects revenue in the range of $1.69-$1.73 billion. The Zacks Consensus Estimate for the same is pegged at $1.74 billion.\nFor 2021, the company expects Screening revenues in the range of $1.12-$1.15 billion, Precision Oncology revenues in the range of $515-$525 million, and COVID-19 testing revenues in the band of $50-$60 million.\nHow Have Estimates Been Moving Since Then?\nIt turns out, fresh estimates have trended upward during the past month. The consensus estimate has shifted 13.7% due to these changes.\nVGM Scores\nAt this time, Exact Sciences has a nice Growth Score of B, however its Momentum Score is doing a bit better with an A. However, the stock was allocated a grade of D on the value side, putting it in the bottom 40% for this investment strategy.\nOverall, the stock has an aggregate VGM Score of C. If you aren't focused on one strategy, this score is the one you should be interested in.\nOutlook\nEstimates have been broadly trending upward for the stock, and the magnitude of these revisions looks promising. Notably, Exact Sciences has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.\nWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. \nClick to get this free report\n \n\nExact Sciences Corporation (EXAS) : Free Stock Analysis Report\n \n\nTo read this article on Zacks.com click here.","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2140420519"}